Newpram Tablet 10mg (Escitalopram Oxalate)

Adult dosage

Safety has not been established for doses exceeding 20 mg per day. This medication is administered once daily, in the morning or evening, regardless of meals. 1) Adults (1) Major depressive disorder: The usual dose is 10 mg once daily. The dose may be increased to a maximum of 20 mg per day according to the patient's response. If increasing the dose to 20 mg, increase it at intervals of at least 1 week. Antidepressant effects generally take 2-4 weeks to develop. Even after symptoms resolve, drug treatment for at least 6 months is needed to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: The recommended initial dose is 5 mg once daily for 1 week, followed by an increase to 10 mg once daily. The dose may be increased to a maximum of 20 mg per day according to the patient's response. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term use of this medication for more than 10 weeks in the treatment of panic disorder have not been systematically studied. (3) Social anxiety disorder: The usual dose is 10 mg once daily. Improvement in symptoms generally takes 2-4 weeks. Thereafter, the dose may be reduced to 5 mg per day or increased to a maximum of 20 mg per day according to the patient's response. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment of responding patients has been studied for 6 months and should be considered individually for each patient to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. (4) Generalized anxiety disorder: The initial dose is 10 mg once daily. According to the patient's response, the dose may be increased to a maximum of 20 mg per day after at least 1 week of treatment. A long-term treatment study was conducted in patients who responded to 12 weeks of open-label treatment, with 20 mg once daily administered for at least 6 months. (5) Obsessive-compulsive disorder: The usual dose is 10 mg once daily. The dose may be increased to a maximum of 20 mg per day according to the patient's response. A long-term treatment study was conducted in patients who responded to 16 weeks of open-label treatment, with 10 mg or 20 mg once daily administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition; treatment should be continued for a sufficient period to ensure symptom resolution. If this medication is used long term, the benefit for each patient and the dose should be reassessed regularly. 2) Patients with renal impairment No dose adjustment is needed in patients with mild or moderate renal impairment. Use with caution in patients with severe renal impairment (CLCR < 30㎖/min). 3) Patients with hepatic impairment The recommended initial dose is 5 mg once daily for the first 2 weeks. The dose may be increased to 10 mg per day according to the patient's response. 4) Discontinuation When discontinuing this medication, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medication, allow an interval of at least 14 days. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days must have passed after discontinuing this medication. 6) Other MAO inhibitors, such as linezolid or methylene blue Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after receiving linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medication may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with methylene blue administered by a nonintravenous route (oral tablets or local injection) or with intravenous doses of 1mg/kg or less is unclear.

This medication is an antidepressant used in the treatment of psychiatric disorders such as major depression. Particularly, there may be an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults aged 18 to 24, so physicians should carefully assess the risks and benefits before prescribing this medication. This medication should not be used in conjunction with specific drugs; for example, patients taking MAO inhibitors or pimozide, or drugs that prolong the QT interval, should not use this medication. Patients with closed-angle glaucoma or a history of glaucoma should use this medication with caution, as it may dilate pupils and increase intraocular pressure. During the initial 1-2 weeks of treatment, various side effects such as anxiety, insomnia, dizziness, and nausea may commonly occur and tend to improve over time. Patients or caregivers should closely monitor for atypical behavioral changes, such as worsening depressive symptoms, suicidal thoughts, or aggression, during the use of this medication. In addition, abrupt discontinuation of this medication may lead to withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so the dosage should be gradually reduced under physician supervision. Patients with heart disease or at risk of QT interval prolongation should be monitored during administration, and those with hypokalemia or hypomagnesemia should correct these conditions beforehand. Women who are pregnant or breastfeeding should consult their physician regarding the use of this medication, especially during the late stages of pregnancy as it may affect the newborn. Elderly patients are advised to start at a lower dosage, and diabetic patients should closely monitor their blood glucose control. It is advisable not to take this medication with alcohol, and caution should be exercised when combining with other serotonin-active drugs due to the risk of serotonin syndrome, which is a serious adverse effect. Lastly, caution should be exercised when driving or operating machinery during the use of this medication, so patients should carefully observe their own condition.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, irritability, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbance, tremor, taste disturbance, sleep disorder, fainting, serotonin syndrome, movement disorders, motor dysfunction, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, ECG QT prolongation, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, nosebleed, nausea, diarrhea, constipation, vomiting, dry mouth, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, xerostomia, abdominal pain, dyspepsia, enteritis, sensory disturbance, cough, asthma, dyspnea, fracture, palpitations, hypertension, paralysis, extrapyramidal disorder, migraine, chest pain, frequent urination, tremors, emotional instability, hypersensitivity, visual impairment, dizziness, sleep disorder, anxiety, agitation, tremor, confusion, sweating, diarrhea

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also important to maintain a temperature between 1 to 30 degrees Celsius while storing the medication to preserve its effectiveness and prevent deterioration.

Appearance

White rectangular film-coated tablets

Package unit

30 tablets/bottle, 200 tablets/bottle